Literature DB >> 8748856

Middle fossa sub-Gasserian ganglion approach to clivus chordomas.

A Goel1.   

Abstract

A modified lateral subtemporal, transpetrous apex and sub-Gasserian ganglion approach was found to be most suitable for clival chordomas. The approach selection was based on the typical anatomical relationship of chordomas in terms of site of origin, pattern of growth and neural and vascular displacements. The approach was suitable to deal with tumour anterior and lateral to the brain stem, the clival part of the tumour and its sub-cavernous sinus extensions. The carotid artery was under control. The approach had the advantage of being simple and relatively quick and of its familiarity to general neurosurgeons. The tumour could be excised radically and extension of anterior, posterior and inferior exposure was possible.

Entities:  

Mesh:

Year:  1995        PMID: 8748856     DOI: 10.1007/bf01410628

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  24 in total

1.  Anterior transpetrosal-transtentorial approach for sphenopetroclival meningiomas: surgical method and results in 10 patients.

Authors:  T Kawase; R Shiobara; S Toya
Journal:  Neurosurgery       Date:  1991-06       Impact factor: 4.654

2.  Petrosal approach for petroclival meningiomas.

Authors:  O Al-Mefty; J L Fox; R R Smith
Journal:  Neurosurgery       Date:  1988-03       Impact factor: 4.654

3.  Cranial computed tomographic appearance of chondrosarcoma of the base of the skull.

Authors:  R I Grossman; K R Davis
Journal:  Radiology       Date:  1981-11       Impact factor: 11.105

4.  Cranial chondrosarcomas. Report of four cases and review of the literature.

Authors:  A L Bahr; B W Gayler
Journal:  Radiology       Date:  1977-07       Impact factor: 11.105

5.  Chordoma and chondrosarcoma of the cranial base: an 8-year experience.

Authors:  C N Sen; L N Sekhar; V L Schramm; I P Janecka
Journal:  Neurosurgery       Date:  1989-12       Impact factor: 4.654

6.  The role of MR and CT in evaluating clival chordomas and chondrosarcomas.

Authors:  R F Oot; G E Melville; P F New; M Austin-Seymour; J Munzenrider; J Pile-Spellman; M Spagnoli; G M Shoukimas; K J Momose; R Carroll
Journal:  AJR Am J Roentgenol       Date:  1988-09       Impact factor: 3.959

7.  Imaging of cranial chordomas.

Authors:  T C Larson; O W Houser; E R Laws
Journal:  Mayo Clin Proc       Date:  1987-10       Impact factor: 7.616

8.  Chondrosarcoma of the skull base: a series of eight cases.

Authors:  S R Stapleton; P R Wilkins; D J Archer; D Uttley
Journal:  Neurosurgery       Date:  1993-03       Impact factor: 4.654

9.  Chordoma and chondrosarcoma: relationship to the internal carotid artery.

Authors:  A Goel
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

10.  Chordomas of the skull base: MR features.

Authors:  S P Meyers; W L Hirsch; H D Curtin; L Barnes; L N Sekhar; C Sen
Journal:  AJNR Am J Neuroradiol       Date:  1992 Nov-Dec       Impact factor: 3.825

View more
  4 in total

1.  Intradural invasion of chordoma: two case reports.

Authors:  Jorge A Gonzalez-Martinez; Murali Guthikonda; Eduardo Vellutini; Lucia Zamorano; Qinghang Li; William Kupski; Fernando G Diaz
Journal:  Skull Base       Date:  2002-08

Review 2.  Adjuvant radiation therapy and chondroid chordoma subtype are associated with a lower tumor recurrence rate of cranial chordoma.

Authors:  Brian J Jian; Orin G Bloch; Isaac Yang; Seunggu J Han; Derick Aranda; Tarik Tihan; Andrew T Parsa
Journal:  J Neurooncol       Date:  2009-12-02       Impact factor: 4.130

3.  Clivus chordoma in continuity with a large pontine cyst.

Authors:  Christian Herold; Mario Giordano; Takahiko Naka; Venelin Gerganov; Madjid Samii; Amir Samii
Journal:  Skull Base       Date:  2009-03

4.  Cranial Chordoma: A New Preoperative Grading System.

Authors:  Harley Brito da Silva; David Straus; Jason K Barber; Robert C Rostomily; Manuel Ferreira; Laligam N Sekhar
Journal:  Neurosurgery       Date:  2018-09-01       Impact factor: 4.654

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.